The 2019 application cycle is now closed.
Choosing Wisely® is a multi-year effort led by the ABIM Foundation to support and engage physicians in being better stewards of finite health care resources. As part of Choosing Wisely, ASH and other medical societies have developed evidence-based recommendations to prompt conversations between patients and clinicians about the necessity and potential harm of certain procedures.
In 2016, ASH introduced the Choosing Wisely Champions initiative to recognize the efforts of practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.
ASH's 10 evidence-based recommendations designed to prompt conversations between patients and clinicians about the necessity and potential harm of certain procedures
ASH's annual recognition of practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures
Hematology-related tests and procedures to question based on recommendations from other medical societies taking part in Choosing Wisely
An educational presentation designed by the ASH Subcommittee on Stewardship to serve as a companion to the ASH Choosing Wisely list
ASH Choosing Wisely List
The ASH Choosing Wisely list provides 10 recommendations. With input from the Society's membership, the recommendations represent months of careful data analysis and review, and use the most current evidence about management and treatment options.
ASH's Choosing Wisely recommendations include:
1. Don't transfuse more than the minimum number of red blood cell (RBC) units necessary to relieve symptoms of anemia or to return a patient to a safe hemoglobin range (7 to 8 g/dL in stable, non-cardiac, in-patients).
Transfusion of the smallest effective dose of red blood cells (RBCs) is recommended because liberal transfusion strategies do not improve outcomes when compared to restrictive strategies. Unnecessary transfusion generates costs and exposes patients to potential adverse effects without any likelihood of benefit. Clinicians are urged to avoid the routine administration of 2 units of RBCs if 1 unit is sufficient and to use appropriate weight-based dosing of RBCs in children.
2. Don't test for thrombophilia in adult patients with venous thromboembolism (VTE) occurring in the setting of major transient risk factors (surgery, trauma, or prolonged immobility).
Thrombophilia testing is costly and can result in harm to patients if the duration of anticoagulation is inappropriately prolonged or if patients are incorrectly labeled as thrombophilic. Thrombophilia testing does not change the management of venous thromboembolisms (VTEs) occurring in the setting of major transient VTE risk factors. When VTE occurs in the setting of pregnancy or hormonal therapy, or when there is a strong family history plus a major transient risk factor, the role of thrombophilia testing is complex and patients and clinicians are advised to seek guidance from an expert in VTE.
3. Don't use inferior vena cava (IVC) filters routinely in patients with acute venous thromboembolism (VTE).
Inferior vena cava (IVC) filters are costly, can cause harm, and do not have a strong evidentiary basis. The main indication for IVC filters is patients with acute venous thromboembolism (VTE) and a contraindication to anticoagulation, such as active bleeding or a high risk of anticoagulant-associated bleeding. Lesser indications that may be reasonable in some cases include patients experiencing pulmonary embolism (PE) despite appropriate, therapeutic anticoagulation, or patients with massive PE and poor cardiopulmonary reserve. Retrievable filters are recommended over permanent filters with removal of the filter when the risk for PE has resolved and/or when anticoagulation can be safely resumed.
4. Don't administer plasma or prothrombin complex concentrates for non-emergent reversal of vitamin K antagonists (i.e. outside of the setting of major bleeding, intracranial hemorrhage or anticipated emergent surgery).
Blood products can cause serious harm to patients, are costly, and are rarely indicated in the reversal of vitamin K antagonists. In non-emergent situations, elevations in the international normalized ratio are best addressed by holding the vitamin K antagonist and/or by administering vitamin K.
5. Limit surveillance computed tomography (CT) scans in asymptomatic patients following curative-intent treatment for aggressive lymphoma.
Computed tomography (CT) surveillance in asymptomatic patients in remission from aggressive non-Hodgkin lymphoma may be harmful through a small but cumulative risk of radiation-induced malignancy. It is also costly and has not been demonstrated to improve survival. Physicians are encouraged to carefully weigh the anticipated benefits of post-treatment CT scans against the potential harm of radiation exposure.
Due to a decreasing probability of relapse with the passage of time and a lack of proven benefit, CT scans in asymptomatic patients more than two years beyond the completion of treatment are rarely advisable.
6. Don't treat with an anticoagulant for more than three months in a patient with a first venous thromboembolism occurring in the setting of a major transient risk factor.
Anticoagulation is potentially harmful and costly. Patients with a first venous thromboembolism (VTE) triggered by a major, transient risk factor such as surgery, trauma, or an intravascular catheter are at low risk for recurrence once the risk factor has resolved and an adequate treatment regimen with anticoagulation has been completed. Evidence-based and consensus guidelines recommend three months of anticoagulation over shorter or longer periods of anticoagulation in patients with VTE in the setting of a reversible provoking factor. By ensuring a patient receives an appropriate regimen of anticoagulation, clinicians may avoid unnecessary harm, reduce health care expenses, and improve quality of life.
This Choosing Wisely® recommendation is not intended to apply to VTE associated with non-major risk factors (e.g., hormonal therapy, pregnancy, travel-associated immobility, etc.), as the risk of recurrent VTE in these groups is either intermediate or poorly defined.
7. Don't routinely transfuse patients with sickle cell disease (SCD) for chronic anemia or uncomplicated pain crisis without an appropriate clinical indication.
Patients with sickle cell disease (SCD) are especially vulnerable to potential harms from unnecessary red blood cell transfusion. In particular, they experience an increased risk of alloimmunization to minor blood group antigens and a high risk of iron overload from repeated transfusions.
Patients with the most severe genotypes of SCD with baseline hemoglobin (Hb) values in the 7-10 g/dl range can usually tolerate further temporary reductions in Hb without developing symptoms of anemia. Many patients with SCD receive intravenous fluids to improve hydration when hospitalized for management of pain crisis, which may contribute to a decrease in Hb by 1-2 g/dL. Routine administration of red cells in this setting should be avoided. Moreover, there is no evidence that transfusion reduces pain due to vaso-occlusive crises.
8. Don't perform baseline or routine surveillance computed tomography (CT) scans in patients with asymptomatic, early stage chronic lymphocytic leukemia.
In patients with asymptomatic, early-stage chronic lymphocytic leukemia (CLL), baseline and routine surveillance computed tomography (CT) scans do not improve survival and are not necessary to stage or prognosticate patients. CT scans expose patients to small doses of radiation, can detect incidental findings that are not clinically relevant but lead to further investigations, and are costly. For asymptomatic patients with early-stage CLL, clinical staging and blood monitoring is recommended over CT scans.
9. Don't test or treat for suspected heparin-induced thrombocytopenia (HIT) in patients with a low pre-test probability of HIT.
In patients with suspected heparin-induced thrombocytopenia (HIT), use the "4T’s" score to calculate the pre-test probability of HIT. This scoring system uses the timing and degree of thrombocytopenia, the presence or absence of thrombosis, and the existence of other causes of thrombocytopenia to assess the pre-test probability of HIT. HIT can be excluded by a low pre-test probability score (4T’s score of 0-3) without the need for laboratory investigation.
Do not discontinue heparin or start a non-heparin anticoagulant in these low-risk patients because presumptive treatment often involves an increased risk of bleeding, and because alternative anticoagulants are costly.
10. Don't treat patients with immune thrombocytopenic purpura (ITP) in the absence of bleeding or a very low platelet count.
Treatment for immune thrombocytopenic purpura (ITP) should be aimed at treating and preventing bleeding episodes and improving quality of life. Unnecessary treatment exposes patients to potentially serious treatment side effects and can be costly, with little expectation of clinical benefit. The decision to treat ITP should be based on an individual patient’s symptoms, bleeding risk (as determined by prior bleeding episodes, and risk factors for bleeding, such as use of anticoagulants, advanced age, high-risk activities, etc.), social factors (distance from the hospital/travel concerns), side effects of possible treatments, upcoming procedures, and patient preferences.
In the pediatric setting, treatment is usually not indicated in the absence of mucosal bleeding regardless of platelet count. In the adult setting, treatment may be indicated in the absence of bleeding if the platelet count is very low. However, ITP treatment is rarely indicated in adult patients with platelet counts greater than 30,000/microL unless they are preparing for surgery or an invasive procedure, or have a significant additional risk factor for bleeding.
In patients preparing for surgery or other invasive procedures, short-term treatment may be indicated to increase the platelet count prior to the planned intervention and during the immediate post-operative period.
ASH's first five Choosing Wisely recommendations were released in 2013 and highlighted in a manuscript published in Blood. In 2014, the list was updated to include five additional commonly used tests, treatments, and procedures in hematology that physicians and patients should question in certain circumstances. A December 2014 manuscript published in Blood highlights these tests and treatments to question and further describes the methods in development of the list, along with the evidentiary basis of the recommendations.back to top
Non-ASH Choosing Wisely Recommendations Relevant to Hematology
Recognizing the immense benefit of collaboration between medical societies—and to avoid duplicating the efforts of other medical societies taking part in the ABIM Foundation's Choosing Wisely campaign—ASH released a list of hematology-related tests and procedures to question based on recommendations from other medical societies taking part in the initiative.
The five Choosing Wisely recommendations being promoted to hematologists include:
1. Don't image for suspected pulmonary embolism (PE) without moderate or high pre-test probability of PE.
While deep vein thrombosis (DVT) and pulmonary embolism (PE) are relatively common clinically, they are rare in the absence of elevated blood D-Dimer levels and certain specific risk factors. Imaging, particularly computed tomography (CT) pulmonary angiography, is a rapid, accurate, and widely available test, but has limited value in patients who are very unlikely, based on serum and clinical criteria, to have significant value. Imaging is helpful to confirm or exclude PE only for such patients, not for patients with low pre-test probability of PE.
Source: American College of Radiology (ACR). Wording reflects that of the ACR recommendation; other societies have similar recommendations and some explicitly
recommended D-Dimer testing prior to imaging.
2. Don't routinely order thrombophilia testing on patients undergoing a routine infertility evaluation.
There is no indication to order these tests, and there is no benefit to be derived in obtaining them in someone that does not have any history
of bleeding or abnormal clotting and in the absence of any family history. This testing is not a part of the infertility workup. Furthermore, the testing is costly, and there are risks associated with the proposed treatments, which would also not be indicated in this routine population.
Source: American Society for Reproductive Medicine.
3. Don't perform repetitive complete blood count (CBC) and chemistry testing in the face of clinical and lab stability.
Hospitalized patients frequently have considerable volumes of blood drawn (phlebotomy) for diagnostic testing during short periods of time. Phlebotomy is highly associated with changes in hemoglobin and hematocrit levels for patients and can contribute to anemia. This anemia, in turn, may have significant consequences, especially for patients with cardiorespiratory diseases. Additionally, reducing the
frequency of daily unnecessary phlebotomy can result in significant cost savings for hospitals.
Source: Society for Hospital Medicine – Adult Hospital Medicine. Wording reflects that of the Adult Hospital Medicine recommendation; other societies have similar recommendations.
4. Don't transfuse red blood cells for iron deficiency without hemodynamic instability.
Blood transfusion has become a routine medical response despite cheaper and safer alternatives in some settings. Pre-operative patients
with iron deficiency and patients with chronic iron deficiency without hemodynamic instability (even with low hemoglobin levels) should be given oral and/or intravenous iron.
Source: American Association of Blood Banks (AABB).
5. Avoid using positron emission tomography (PET) or PET-CT scanning as part of routine follow-up care to monitor for a cancer recurrence in asymptomatic patients who have finished initial treatment to eliminate the cancer unless there is high-level evidence that such imaging will change the outcome.
Positron emission tomography (PET) and PET-CT are used to diagnose, stage, and monitor how well treatment is working. Available evidence from clinical studies suggests that using these tests to monitor for recurrence does not improve outcomes and therefore generally is not recommended for this purpose. False positive tests can lead to unnecessary and invasive procedures, overtreatment, unnecessary radiation exposure, and incorrect diagnoses.
Until high-level evidence demonstrates that routine surveillance with PET or PET-CT scans helps prolong life or promote well-being after treatment for a specific type of cancer, this practice should not be done.
Source: American Society of Clinical Oncology
Using a rigorous methodology, the ASH Subcommittee on Stewardship scored 400 recommendations for relevance and importance over a series of iterations, resulting in this list of five items deemed to be especially useful to hematologists. As with past ASH lists, harm avoidance was established as the campaign's preeminent guiding principle, with cost, strength of evidence, frequency, relevance, and impact serving as additional factors.back to top
ASH Choosing Wisely Education Slide Set
In support of the Choosing Wisely initiative, the ASH Subcommittee on Stewardship has produced an educational presentation to serve as a companion to the ASH Choosing Wisely list. The presentation describes how the list was created and the underlying evidence supporting the recommendations.
The presentation can be downloaded as a PowerPoint slide deck or a PDF document for printing. Members are encouraged to use the presentation and share it among colleagues.
back to top
- Patient Brochure on IVC Filters
The American Society of Hematology (ASH) and Consumer Reports have created a guide called “Treating Acute Blood Clots: When You Need a Special Device Implanted – and When You Don’t” to promote conversation between patients and their hematologists when considering use of inferior cava filters.
- ASH Pocket Guides
ASH has developed a series of brief, evidence-based pocket guides to help physicians provide quality care to patients.